27.11.2012 Views

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information<br />

EMPLOYEES: 70 employees<br />

G. Todd Nilne, Ph.D.; VP, Biology<br />

James O'Mara; VP, Business Development<br />

John J. Talley, Ph.D.; VP, Drug Discovery<br />

HISTORY: Founded and began biotech R&D in 1998<br />

Member--Biotechnology Industry Organization<br />

STOCK-FINANCIAL HISTORY: Privately held<br />

PRIVATE PLACEMENTS: Raised $9.8M in Series A financing (2/99)<br />

Raised $23M in Series B financing (8/00)<br />

Raised $40M in Series D financing (5/04)<br />

Raised $75M in Series E financing (2/06)<br />

PRINCIPAL INVESTORS: Aberdare Ventures<br />

Alton Ltd.<br />

BancBoston Ventures<br />

Bio*One Capital<br />

Essex Investment Management Co.<br />

Fidelity Biosciences Group<br />

Invus LP<br />

Jennison Associates<br />

Linkagene LP<br />

Maverick Capital<br />

Paperboy Ventures<br />

Polaris Venture Partners<br />

Sigma Capital Management<br />

Venrock Associates<br />

BUSINESS STRATEGY: Utilize revenues from yield improvement service business to fund internal<br />

development of novel anti-infectives<br />

AGREEMENTS: Name Products Content of Agreement Date<br />

DuPont Central biomanufacturing CRADA with 2/06<br />

Research & process for a chemical Microbia's Precision<br />

Development currently manufactured Engineering®<br />

from petrochemicalbased<br />

raw materials<br />

business unit<br />

Ranbaxy<br />

biomanufacturing technology<br />

2/03<br />

Laboratories Ltd. processes using development<br />

Microbia’s Precision<br />

Engineering<br />

agreement<br />

Ranbaxy<br />

to lower the cost of a research<br />

11/05<br />

Laboratories Ltd. Ranbaxy<br />

biomanufacturing<br />

process<br />

collaboration<br />

Teva<br />

biomanufacturing development 3/04<br />

Pharmaceutical processes using agreement,<br />

Industries<br />

Microbia’s Precision<br />

Engineering technology<br />

expanded<br />

RESEARCH & DEVELOPMENT: Precision Engineering platform: Applies molecular genetics and proprietary<br />

profiling methods to rationally design microbes for the efficient production of<br />

commercially valuable metabolites. Applications include the pharmaceutical,<br />

food and feed ingredients, specialty chemical industries and industrial<br />

biotechnology<br />

Copyright ©2006 AHC Media ® 242

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!